We have collected information about Targeted Delivery Of Plk1 Sirna for you. Follow the links to find out details on Targeted Delivery Of Plk1 Sirna.
https://stm.sciencemag.org/content/4/130/130ra48.full
Apr 18, 2012 · Treatment with F5-P/PLK1-siRNA significantly prolonged survival of mice injected with BT474 cells but had no survival benefit for mice harboring MDA-MB-231 metastases . Therefore, F5-P–mediated delivery of PLK1-siRNA specifically reduced experimental metastasis and prolonged survival of mice with Her2 + breast tumors.Author: Yan-dan Yao, Tian-meng Sun, Song-yin Huang, Shuang Dou, Ling Lin, Jia-ning Chen, Jian-bin Ruan, Chen...
https://www.researchgate.net/publication/224770279_Targeted_Delivery_of_PLK1-siRNA_by_ScFv_Suppresses_Her2_Breast_Cancer_Growth_and_Metastasis
Apr 18, 2012 · Targeted Delivery of PLK1-siRNA by ScFv Suppresses Her2. ... breast cancer growth and metastasis in vitro. and in vivo by inducing cell cycle arre st and apoptosis, without triggering.
https://stm.sciencemag.org/content/scitransmed/4/130/130ra48.full.pdf
BREAST CANCER Targeted Delivery of PLK1-siRNA by ScFv Suppresses Her2+ Breast Cancer Growth and Metastasis Yan-dan Yao,1* Tian-meng Sun,2* Song-yin Huang,1 Shuang Dou,2 Ling Lin,1 Jia-ning Chen,1 Jian-bin Ruan,2 Cheng-qiong Mao,2 Feng-yan Yu,1 Mu-sheng Zeng,3 Jian-ye Zang,2 Qiang Liu,1 Feng-xi Su,1 Peter Zhang,4 Judy Lieberman,5† Jun Wang,2† Erwei Song1† A major obstacle to …Author: Yan-dan Yao, Tian-meng Sun, Song-yin Huang, Shuang Dou, Ling Lin, Jia-ning Chen, Jian-bin Ruan, Chen...
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5445934/
Herein, we report for the first time that the same platform can act as a targeted siRNA delivery system to metastatic breast tumors. For the siRNA target, we chose polo-like kinase 1 (PLK1), which is involved in cell division and DNA damage response and is found in actively dividing cancer cells .Author: Jingga Morry, Worapol Ngamcherdtrakul, Shenda Gu, Moataz Reda, David J. Castro, Thanapon Sangvanich,...
https://www.ncbi.nlm.nih.gov/pubmed/28138033
Metastatic breast cancer is developed in about 20% to 30% of newly diagnosed patients with early-stage breast cancer despite treatments. Herein, we report a novel nanoparticle platform with intrinsic antimetastatic properties for the targeted delivery of Polo-like kinase 1 siRNA (siPLK1).Author: Jingga Morry, Worapol Ngamcherdtrakul, Shenda Gu, Moataz Reda, David J. Castro, Thanapon Sangvanich,...
https://www.sciencedirect.com/science/article/pii/S1818087614000646
For siRNA targeted delivery, peptides, antibodies and aptamers have been used. For the receptor-ligand mediated delivery of siRNA, the carboxylic acid group of a peptide mimetic of IGF1, D-(Cys-Ser-Lys-Cys), was activated and conjugated to an amine group of the 5′-sense strand of siRNA.Author: Cong-fei Xu, Jun Wang
https://www.hindawi.com/journals/jdd/2017/6971297/
Over the past 20 years, a diverse group of ligands targeting surface biomarkers or receptors has been identified with several investigated to target siRNA to tumors. Many approaches to developing tumor-homing peptides, RNA and DNA aptamers, and single-chain variable fragment antibodies by using phage display, in vitro evolution, and recombinant antibody methods could not have been imagined by ...Author: Qixin Leng, Martin C. Woodle, A. James Mixson
https://www.nature.com/articles/nmat3765
Oct 23, 2013 · Therapeutics based on small interfering RNA (siRNA), which in principle are able to reversibly silence any gene of interest, are under development for the …Author: Rosemary Kanasty, Joseph Robert Dorkin, Arturo Vegas, Arturo Vegas, Daniel Anderson
https://www.ohsu.edu/sites/default/files/2019-06/WY2%20763-full.pdf
Models and Technologies Targeted Treatment of Metastatic Breast Cancer by PLK1 siRNA Delivered by an Antioxidant Nanoparticle Platform Jingga Morry1,Worapol Ngamcherdtrakul1,2, Shenda Gu1, Moataz Reda1, David J. Castro1,2,Thanapon Sangvanich1, Joe W. Gray1, and Wassana Yantasee1,2 Abstract
https://mct.aacrjournals.org/content/16/4/763
Apr 01, 2017 · In contrast, siRNA can be designed to target only PLK1 and thus have less toxicity to non-cancer cells than BI2536 . An siRNA against PLK1 (TKM-080301) has been in phase I/II trials by Arbutus Biopharma, but the delivery platform has no targeting agent and is lipid-based that is homing for liver.Author: Jingga Morry, Worapol Ngamcherdtrakul, Shenda Gu, Moataz Reda, David J. Castro, Thanapon Sangvanich,...
Searching for Targeted Delivery Of Plk1 Sirna?
You can just click the links above. The data is collected for you.
